Greg Duncan, Virios Therapeutics CEO
September 19, 2022 11:09 AM EDTUpdated 11:28 AM
R&D

Blam­ing Covid-19 for ini­tial da­ta is­sues, an­tivi­ral biotech re­ports PhI­Ib fi­bromyal­gia fail — shares tank

Paul Schloesser

Associate Editor

Close to two years af­ter mak­ing the jump to Nas­daq and rais­ing $30 mil­lion via IPO, Virios Ther­a­peu­tics has failed on a mid-stage study and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times